Targeting cell death signalling in cancer: Minimising 'Collateral damage'

British Journal of Cancer

Volumn 115, Issue 1, 2016, Pages 5-11

  Fox, Joanna L ^a   MacFarlane, Marion ^a  

^a MRC TOXICOLOGY UNIT   (United Kingdom)

Author keywords

adverse effects; BCL 2 family; cancer; cell death; IAPs; SMAC mimetics; targeted therapies; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; CELL DEATH PROTEIN; CELL PROTEIN; UNCLASSIFIED DRUG; INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN BCL 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CHEMOSENSITIZATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANIMAL; DRUG EFFECTS; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84965034325     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.111     Document Type: Article

References (54)

1. Amaravadi RK, Schilder RJ, Martin LP, Levin M, Graham MA, Weng DE, Adjei AA. (2015). A phase 1 study of the SMAC-mimetic birinapant in adults with refractory solid tumors or lymphoma. Mol Cancer Ther 14: 2569-2575
2. Belmar J, Fesik SW. (2015). Small molecule Mcl-1 inhibitors for the treatment of cancer. Pharmacol Ther 145: 76-84
3. Berger A, Quast SA, Plotz M, Kammermeier A, Eberle J. (2013). Sensitization of melanoma cells for TRAIL-induced apoptosis by BMS-345541 correlates with altered phosphorylation and activation of Bax. Cell Death Dis 4: e477
4. Bucur O, Gaidos G, Yatawara A, Pennarun B, Rupasinghe C, Roux J, Andrei S, Guo B, Panaitiu A, Pellegrini M, Mierke DF, Khosravi-Far R. (2015). A novel caspase 8 selective small molecule potentiates TRAIL-induced cell death. Sci Rep 5: 9893
5. Busacca S, Law EW, Powley IR, Proia DA, Sequeira M, Le Quesne J, Klabatsa A, Edwards JM, Matchett KB, Luo JL, Pringle JH, El-Tanani M, MacFarlane M, Fennell DA. (2015). Resistance to HSP90 inhibition involving loss of MCL1 addiction. Oncogene 35(12): 1483-1492
6. Colin DJ, Hain KO, Allan LA, Clarke PR. (2015). Cellular responses to a prolonged delay in mitosis are determined by a DNA damage response controlled by Bcl-2 family proteins. Open Biol 5(3): 140156
7. Dickens LS, Boyd RS, Jukes-Jones R, Hughes MA, Robinson GL, Fairall L, Schwabe JW, Cain K, MacFarlane M. (2012). A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death. Mol Cell 47(2): 291-305
8. Dickens LS, Powley IR, Hughes MA, MacFarlane M. (2012). The complexities of life and death: death receptor signalling platforms. Exp Cell Res 318(11): 1269-1277
9. Dyer MJ, MacFarlane M, Cohen GM. (2007). Barriers to effective TRAIL-Targeted therapy of malignancy. J Clin Oncol 25(28): 4505-4506
10. Fox JL, Ismail F, Azad A, Ternette N, Leverrier S, Edelmann MJ, Kessler BM, Leigh IM, Jackson S, Storey A. (2010). Tyrosine dephosphorylation is required for Bak activation in apoptosis. EMBO J 29(22): 3853-3868
11. Fox JL, Storey A. (2015). BMX negatively regulates BAK function, thereby increasing apoptotic resistance to chemotherapeutic drugs. Cancer Res 75(7): 1345-1355
12. Fresquet V, Rieger M, Carolis C, Garcia-Barchino MJ, Martinez-Climent JA. (2014). Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood 123(26): 4111-4119
13. Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, Buchler P, Haas TL, Schader MB, Untergasser A, Stremmel W, Walczak H. (2006). Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 12(8): 2640-2646
14. Han B, Park D, Li R, Xie M, Owonikoko TK, Zhang G, Sica GL, Ding C, Zhou J, Magis AT, Chen ZG, Shin DM, Ramalingam SS, Khuri FR, Curran WJ, Deng X. (2015). Small-molecule Bcl2 BH4 antagonist for lung cancer therapy. Cancer Cell 27(6): 852-863
15. Hanahan D, Weinberg RA. (2011). Hallmarks of cancer: the next generation. Cell 144(5): 646-674
16. Haselmann V, Kurz A, Bertsch U, Hubner S, Olempska-Muller M, Fritsch J, Hasler R, Pickl A, Fritsche H, Annewanter F, Engler C, Fleig B, Bernt A, Roder C, Schmidt H, Gelhaus C, Hauser C, Egberts JH, Heneweer C, Rohde AM, Boger C, Knippschild U, Rocken C, Adam D, Walczak H, Schutze S, Janssen O, Wulczyn FG, Wajant H, Kalthoff H, Trauzold A. (2014). Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells. Gastroenterology 146(1): 278-290
17. Hughes MA, Harper N, Butterworth M, Cain K, Cohen GM, MacFarlane M. (2009). Reconstitution of the death-inducing signaling complex reveals a substrate switch that determines CD95-mediated death or survival. Mol Cell 35(3): 265-279
18. Hughes MA, Powley IR, Jukes-Jones R, Horn S, Feoktistova M, Fairall L, Schwabe JW, Leverkus M, Cain K, MacFarlane M. (2016). Co-operative and hierarchical binding of c-FLIP and Caspase-8: a unified model defines how c-FLIP isoforms differentially control cell fate. Mol Cell 61(6): 834-849
19. Ichim G, Lopez J, Ahmed SU, Muthalagu N, Giampazolias E, Delgado ME, Haller M, Riley JS, Mason SM, Athineos D, Parsons MJ, van de Kooij B, Bouchier-Hayes L, Chalmers AJ, Rooswinkel RW, Oberst A, Blyth K, Rehm M, Murphy DJ, Tait SW. (2015). Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Mol Cell 57(5): 860-872
20. Infante JR, Dees EC, Olszanski AJ, Dhuria SV, Sen S, Cameron S, Cohen RB. (2014). Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. J Clin Oncol 32(28): 3103-3110
21. Jeon YJ, Middleton J, Kim T, Lagana A, Piovan C, Secchiero P, Nuovo GJ, Cui R, Joshi P, Romano G, Di Leva G, Lee BK, Sun HL, Kim Y, Fadda P, Alder H, Garofalo M, Croce CM. (2015). A set of NF-kappaB-regulated microRNAs induces acquired TRAIL resistance in lung cancer. Proc Natl Acad Sci USA 112(26): E3355-E3364
22. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC. (2000). Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6(5): 564-567
23. Kim MS, Kim SS, Yoo NJ, Lee SH. (2012). Rare somatic mutation of pro-Apoptotic BAX and BAK genes in common human cancers. Tumori 98(6): 149e-151e
24. Lee DH, Sung KS, Bartlett DL, Kwon YT, Lee YJ. (2015). HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells. Cell Signal 27(2): 293-305
25. Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, Lee JH, Han SY, Park JY, Oh RR, Kang CS, Kim KM, Jang JJ, Nam SW, Lee JY, Yoo NJ. (2001). Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkins lymphoma. Oncogene 20(3): 399-403
26. Leverkus M, Neumann M, Mengling T, Rauch CT, Brocker EB, Krammer PH, Walczak H. (2000). Regulation of tumor necrosis factor-related apoptosisinducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 60(3): 553-559
27. Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J, Nimmer P, Jin S, Smith M, Xiao Y, Kovar P, Tanaka A, Bruncko M, Sheppard GS, Wang L, Gierke S, Kategaya L, Anderson DJ, Wong C, Eastham-Anderson J, Ludlam MJ, Sampath D, Fairbrother WJ, Wertz I, Rosenberg SH, Tse C, Elmore SW, Souers AJ. (2015). Potent and selective small-molecule MCL-1 inhibitors demonstrate on-Target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis 6: e1590
28. Lim B, Allen JE, Prabhu VV, Talekar MK, Finnberg NK, El-Deiry WS. (2015). Targeting TRAIL in the treatment of cancer: new developments. Expert Opin Ther Targets 19(9): 1171-1185
29. Lovric MM, Hawkins CJ. (2010). TRAIL treatment provokes mutations in surviving cells. Oncogene 29(36): 5048-5060
30. MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM. (2005). TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res 65(24): 11265-11270
31. MacFarlane M, Robinson GL, Cain K. (2012). Glucose-A sweet way to die: metabolic switching modulates tumor cell death. Cell Cycle 11(21): 3919-3925
32. Meynet O, Beneteau M, Jacquin MA, Pradelli LA, Cornille A, Carles M, Ricci JE. (2012). Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis. Leukemia 26(5): 1145-1147
33. Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Janne PA, Amrein PC, Cichowski K, Drapkin R, Letai A. (2015). Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 160(5): 977-989
34. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P, Tai YT, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, Deangelo DJ, McConkey DJ, Sallan SE, Silverman L, Hirsch MS, Carrasco DR, Letai A. (2011). Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 334(6059): 1129-1133
35. Papadopoulos KP, Isaacs R, Billic S, Kentsch K, Huet HA, Hofmann M, Rasco D, Kundamal N, Tang Z, Cooksey J, Mahipal A. (2015). Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobodys targeting the DR5 receptor. Cancer Chemother Pharmacol 75: 887-895
36. Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M, Temirov J, Cleland MM, Pelletier S, Schuetz JD, Youle RJ, Green DR, Opferman JT. (2012). Anti-Apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol 14(6): 575-583
37. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J, Harran P, Wang X. (2007). Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12(5): 445-456
38. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF. (2016). Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 374(4): 311-322
39. Robinson GL, Dinsdale D, MacFarlane M, Cain K. (2012). Switching from aerobic glycolysis to oxidative phosphorylation modulates the sensitivity of mantle cell lymphoma cells to TRAIL. Oncogene 31(48): 4996-5006
40. Shi J, Zhou Y, Huang HC, Mitchison TJ. (2011). Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL. Cancer Res 71(13): 4518-4526
41. Sochalska M, Tuzlak S, Egle A, Villunger A. (2015). Lessons from gain-And loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy. FEBS J 282(5): 834-849
42. Tchoghandjian A, Jennewein C, Eckhardt I, Momma S, Figarella-Branger D, Fulda S. (2014). Smac mimetic promotes glioblastoma cancer stem-like cell differentiation by activating NF-kappaB. Cell Death Differ 21(5): 735-747
43. Tchoghandjian A, Jennewein C, Eckhardt I, Rajalingam K, Fulda S. (2013). Identification of non-canonical NF-kappaB signaling as a critical mediator of Smac mimetic-stimulated migration and invasion of glioblastoma cells. Cell Death Dis 4: e564
44. Thomas RL, Roberts DJ, Kubli DA, Lee Y, Quinsay MN, Owens JB, Fischer KM, Sussman MA, Miyamoto S, Gustafsson AB. (2013). Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev 27(12): 1365-1377
45. Varadarajan S, Butterworth M, Wei J, Pellecchia M, Dinsdale D, Cohen GM. (2013). Sabutoclax (BI97C1) and BI112D1, putative inhibitors of MCL-1, induce mitochondrial fragmentation either upstream of or independent of apoptosis. Neoplasia 15(5): 568-578
46. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, Zobel K, Dynek JN, Elliott LO, Wallweber HJ, Flygare JA, Fairbrother WJ, Deshayes K, Dixit VM, Vucic D. (2007). IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 131(4): 669-681
47. Vela L, Marzo I. (2015). Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside. Curr Opin Pharmacol 23: 74-81
48. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, Benetatos CA, Chunduru SK, Condon SM, McKinlay M, Brink R, Leverkus M, Tergaonkar V, Schneider P, Callus BA, Koentgen F, Vaux DL, Silke J. (2007). IAP antagonists target cIAP1 to induce TNFalphadependent apoptosis. Cell 131(4): 682-693
49. Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, Deangelo DJ, Frattini MG, Letai A. (2012). Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 151(2): 344-355
50. Volkmann X, Fischer U, Bahr MJ, Ott M, Lehner F, MacFarlane M, Cohen GM, Manns MP, Schulze-Osthoff K, Bantel H. (2007). Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 46(5): 1498-1508
51. von Karstedt S, Conti A, Nobis M, Montinaro A, Hartwig T, Lemke J, Legler K, Annewanter F, Campbell AD, Taraborrelli L, Grosse-Wilde A, Coy JF, El-Bahrawy MA, Bergmann F, Koschny R, Werner J, Ganten TM, Schweiger T, Hoetzenecker K, Kenessey I, Hegedus B, Bergmann M, Hauser C, Egberts JH, Becker T, Rocken C, Kalthoff H, Trauzold A, Anderson KI, Sansom OJ, Walczak H. (2015). Cancer cell-Autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. Cancer Cell 27(4): 561-573
52. Wang P, Lindsay J, Owens TW, Mularczyk EJ, Warwood S, Foster F, Streuli CH, Brennan K, Gilmore AP. (2014). Phosphorylation of the proapoptotic BH3-only protein bid primes mitochondria for apoptosis during mitotic arrest. Cell Rep 7(3): 661-671
53. Warburg O. (1956). On respiratory impairment in cancer cells. Science 124(3215): 269-270
54. Yu L, Liu S. (2013). Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics. Semin Cancer Biol 23(6 Pt B): 553-560